Is Now the Time to Invest in Agios Pharmaceuticals, Inc?

Agios Pharmaceuticals reported surprisingly strong results for an early stage blood cancer drug candidate today. Should you dig deeper into this story?

Apr 7, 2014 at 11:15AM

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited objective responses, with three showing complete remissions. The drug's safety profile also appears favorable, with only a couple of adverse events occurring so far, although the trial is still in its early days. These data are being presented today at a Clinical Trials Symposium at the American Association for Cancer Research. Agios is developing AG-221 in collaboration with Celgene, which owns the worldwide rights to the drug. 

Thus far, the ongoing study has enrolled 22 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome that harbor the IDH2 mutation. Cells with the IDH2 mutation produce increased levels of an oncometabolite believed to prevent normal bone marrow cells from maturing, whereby causing cancer. Agios' orally available drug functions by inhibiting the expression of this mutated protein, thus lowering the levels of the undesirable oncometabolite.

What's key to understand is that the overall survival rate for patients with these specific types of blood cancers is generally less than 10%. Put simply, the standard therapies are essentially ineffective and new treatment modalities are needed.

Is Agios' early stage drug worth keeping tabs on?
Despite these initially strong results, I believe it's important to keep our enthusiasm in check going forward. There is a good reason why the treatment options for these types of blood cancers are limited. For instance, Geron's (NASDAQ:GERN) telomerase-inhibitor imetelstat also showed strong early signals of efficacy in a handful of blood cancers, including AML. However, the U.S. Food and Drug Administration has since placed a clinical hold on the therapy over toxicity concerns.

Additionally, Sunesis Pharmaceuticals (NASDAQ:SNSS) recently reported that it is delaying a late-stage data readout for its AML candidate vosaroxin after patients were reported to be surviving longer than expected. Although this delay could be meaningless, there is a chance that Sunesis may have one of the first effective treatments for AML, which would likely affect AG-221's commercial aspirations. Overall, there are still a lot of moving parts to this story. So I recommend investors exercise caution with these early stage, albeit promising, trial results.      
 

This stock could make you wealthy
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers